Berkshire Hathaway (BRKB) Stock Is the Financial Stock I'd Still Want to Own in 2036, and Not Because of Warren Buffett

Berkshire Hathaway is presented as a long-term defensive holding following Warren Buffett's CEO succession to Greg Abel in early 2026. The company, valued at more than $1 trillion, delivered share-price appreciation of over 6,000,000%—nearly 20% annually—over 60 years, versus roughly 46,000% for the S&P 500. The bullish thesis centers on its diversified insurance, energy, rail and consumer businesses, along with share repurchases and Abel's acquisition of homebuilder Taylor Morrison.

Analysis

This is not independently investable news: the succession, acquisition, and repurchase assertions require confirmation through Berkshire filings and formal disclosures before assigning earnings value. The relevant market question is whether post-Buffett capital allocation changes Berkshire's persistent valuation framework—from a float-plus-operating-businesses compounder to a more conventional conglomerate deserving a lower multiple if cash deployment becomes less disciplined. Near term, BRK.B is more likely to trade on equity-market beta, insurance pricing, and the mark-to-market value of concentrated public holdings than on retail commentary.

A verified homebuilder acquisition would create a non-obvious offset: it increases Berkshire's sensitivity to mortgage rates, land inflation, and cyclical housing demand just as its regulated utility and insurance earnings provide ballast. TMHC would benefit from Berkshire's balance sheet and lower financing risk, but Berkshire shareholders should demand acquisition returns above what excess cash could earn in repurchases or short-duration Treasuries; otherwise, conglomerate-discount risk rises over 6-18 months. AAPL, AXP, and BAC remain important look-through exposures, meaning a consumer-credit deterioration would pressure both Berkshire's operating insurance results and investment portfolio sentiment.

Contrarianly, a succession-related multiple discount could be an opportunity rather than a structural break if underwriting discipline, cash generation, and decentralized operating margins remain intact through the next two reporting cycles. The thesis is falsified by sustained deterioration in insurance combined ratios, a material decline in operating earnings excluding investment gains, or large acquisitions at returns below Berkshire's cost of capital; absent verified changes, this article alone does not justify a directional trade.

Key Decisions for Investors

• No immediate trade from this article. Verify any TMHC transaction and its purchase price, financing, and expected return on capital in Berkshire disclosures; treat it as a watch item, not a catalyst, until confirmed.
• For existing BRK.B exposure, maintain a 1-3 month monitoring framework around quarterly operating earnings: reduce if insurance underwriting weakens materially while repurchases cease and cash is deployed into low-return acquisitions.
• If verified succession concerns create a 10-15% BRK.B underperformance versus the S&P 500 without a corresponding decline in operating earnings or insurance pricing, consider a 6-12 month long BRK.B / short SPY pair; target normalization of half the relative drawdown, with stop-loss on a further 7% relative decline or adverse capital-allocation disclosure.
• For a confirmed TMHC acquisition, avoid chasing TMHC after the announcement premium. The cleaner expression is to reassess BRK.B only after deal economics are disclosed; a high multiple of tangible book or aggressive housing-cycle assumptions would favor underweight BRK.B versus diversified insurers such as CB or PGR.